Autopsy report · NCT00313144
Aralast alpha1-proteinase Inhibitor Surveillance Study
Cause of deathFunding or business
“Study terminated early due to Aralast being phased out of the market.”
Life of this trial
- Registered 2 months before it started.
- Ran for about 2 years 11 months before it stopped.
- 127 participants enrolled.
- Results were posted on the registry 2 years 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 4
- Sponsor
- Baxalta now part of Shire
- Sponsor type
- Industry
- Conditions
- Alpha1-antitrypsin Deficiency
- Interventions
- ARALAST Alpha1-Proteinase Inhibitor
- Participants
- 127
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Intracoronary Bolus Only Compared With Intravenous Bolus and 12-hours Infusion of Abciximab in Non-ST Elevation Myocardial Infarction.
“The study was terminated early due to a shortage of research and analytical personnel, which prevented the completion of the study as planned” - Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma
“The study terminated due to funding ending.” - A Study of Tadalafil for Duchenne Muscular Dystrophy
“The study is being terminated for lack of efficacy” - A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
“Study terminated as part of strategic considerations” - Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients
“Study was terminated early for strategic reasons. Only Part I of the study was completed.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.